clinical trial · NCT04826159
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
Imbria Pharmaceuticals, Inc.·phase2·completed·n = 49
Type 2 DiabetesDiabetic CardiomyopathiesHFpEF - Heart Failure With Preserved Ejection FractionIMB-1018972
brief summary
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
started
Apr 21, 2021
primary completion
Aug 6, 2024
completion
Aug 6, 2024
last updated
Jun 29, 2025
official title
A Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients With Type 2 Diabetes.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol